Anzeige
Meldung des Tages: +52% am Freitag und das könnte erst der Anfang sein: Zefiro sichert sich millionenschwere Staatsaufträge

Viatris News

Aktie
WKN:  A2QAME ISIN:  US92556V1061 US-Symbol:  VTRS Branche:  Pharmazeutika Land:  USA
12,272 €
-0,198 €
-1,59%
14:49:43 Uhr
Depot/Watchlist
Marktkapitalisierung *
12,24 Mrd. €
Streubesitz
12,81%
KGV
-23,49
Dividende
0,42 EUR
Dividendenrendite
4,11%
Nachhaltigkeits-Score
42 %
Index-Zuordnung
S&P 500

Viatris News

13.04.26 - PR Newswire
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 PR Newswire
10.04.26 - PR Newswire
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting PR Newswire
23.03.26 - PR Newswire
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) PR Newswire
19.03.26 - PR Newswire
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 PR Newswire
26.02.26 - PR Newswire
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Viatris Reports Fourth-​Quarter and Full-Year 2025 Financial Results PR Newswire
26.02.26 - PR Newswire
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend PR Newswire
25.02.26 - PR Newswire
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia PR Newswire
03.02.26 - PR Newswire
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 PR Newswire
03.02.26 - PR Newswire
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Viatris Appoints Matthew J. Maletta as Chief Legal Officer PR Newswire
20.01.26 - PR Newswire
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure PR Newswire
08.01.26 - PR Newswire
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer PR Newswire
18.12.25 - PR Newswire
Viatris Provides Pipeline Update on Four Regulatory Milestones
Viatris Provides Pipeline Update on Four Regulatory Milestones PR Newswire
17.12.25 - PR Newswire
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
06.12.25 - PR Newswire
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited PR Newswire
24.11.25 - PR Newswire
Viatris to Participate in Upcoming Investor Conferences
Viatris to Participate in Upcoming Investor Conferences PR Newswire
19.11.25 - PR Newswire
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und ...
19.11.25 - PR Newswire
European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe
European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for ...
13.11.25 - PR Newswire
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025 PR Newswire
06.11.25 - PR Newswire
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance PR Newswire
04.11.25 - PR Newswire
Viatris Announces Quarterly Dividend
Viatris Announces Quarterly Dividend PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr -1,94%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »